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The effects of pentoxifylline on the relative perfusion of tumours growing
in three sites in the mouse
P.L. Sensky, V.E. Prise, A.E.M. Ward & D.G. Hirst
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Summary The haemorheological agent pentoxifylline (PTX) has been shown to improve the relative perfusion
and oxygenation of subcutaneous tumours in the mouse. In order to establish whether this effect is dependent
on the site of tumour growth, we have looked at changes in the distribution of the cardiac output (COD) to
the murine NT carcinoma grown either intradermally (i.d.), intramuscularly (i.m.), on the wall of the caecum,
or in all three sites, following i.p. administration of 50 mg kg-' PTX. In animals bearing a single tumour, PTX
treatment significantly increases the COD to tumours located in the caecum, but has no significant effect on
the COD to those located in the i.d. or i.m. sites. If all three tumours are present in a single animal, the COD
to all three tumours is significantly enhanced by PTX. This appears to reflect the presence of the caecum
tumour and does not appear to relate to changes in tumour size or to the haematocrit (HCT) of the blood. We
propose that this site dependency implies that a significant increase in blood viscosity only occurs in animals
with tumours located in specific sites. Therefore, the potential radiosensitising capability of PTX is highly
dependent on tumour location.
Tumour perfusion is governed by the arteriovenous pressure
gradient across the vascular bed and by the resistance that
the blood encounters within the microvasculature. Resistance
to flow arises from the geometric structure of the blood
vessels and from the viscosity of the perfusing blood. Unlike
normal tissues, the heterogeneity and transient nature of the
tumour microvasculature gives rise to regions where blood
flow becomes sluggish and may even occur in a retrograde
direction (see Jain, 1988, for review). This results in
haemoconcentration within the tumour, thus increasing the
viscosity of the blood as it passes through the tumour micro-
circulation. Since the delivery of therapeutic drugs to
tumours would be enhanced by an increase in tumour per-
fusion rate, the benefits of reducing blood viscosity, and
therefore the flow resistance, are self evident.
The methyl xanthine derivative, pentoxifylline (PTX), a
drug used clinically for the treatment of intermittent
claudication and peripheral vascular disease, is known to
lower blood viscosity both directly, by increasing the defor-
mability of erythrocytes (Dormandy et al., 1981; Carr &
Hauge, 1990), and indirectly, by preventing the formation of
clusters of red cells, or rouleaux, via the stimulation of
fibrinolysis resulting from the release ofprostacyclin from the
endothelial cells (Jarrett et al., 1977; Muller, 1979; Matzky et
al., 1982). By reducing the rigidity of the red cells, their
passage through small arterioles and capillaries, such as those
present in the tumour microcirculation, is improved.
Whilst the treatment of peripheral vascular disorders is the
principal use for PTX, its multifaceted haemorheological pro-
perties have resulted in it being used in numerous therapeutic
trials, including treatment for cerebrovascular disease,
ischaemic heart disease and sickle cell disease (see Ward &
Clissold, 1987, for review). Its place as a potential radiosen-
sitiser for cancer therapy has been investigated in a number
of studies on subcutaneous murine tumours, in which PTX
treatment was shown to improve tumour perfusion and oxy-
genation, as well as enhancing growth delay following X-
irradiation (Lee et al., 1992; Song et al., 1992; Honess,
1991).
Recent studies have demonstrated that tumour site is an
important determinant of tumour response to various
vasoactive agents and to induced anaemia (Hirst et al., 1991;
Hirst et al., 1993; Sensky et al., in press). We therefore
wished to determine if the tumour response to PTX was also
site dependent. In this study, we have compared the effects of
PTX on the distribution of the cardiac output (COD) to
tumours implanted in one or each of three sites, located
intradermally (i.d.), intramuscularly (i.m.), or on the wall of
the caecum. The relative effectiveness of PTX following an
increase in tumour size or a reduction in haematocrit is also
investigated.
Methods
Animals and tumours
The NT carcinoma (CaNT), a transplantable mammary
adenocarcinoma, was used in syngeneic CBA male 8-week-
old mice in all experiments. The transplants in the three sites
were staggered so that they all reached a treatable size on the
same day.
A single suspension of tumour cells was prepared in
physiological saline. Three to 5 x I05cells were inoculated
intradermally (i.d.) on the back in a volume of 50 ;l. Three
days post-transplant, a 0.5-1.0mm3 tumour fragment was
applied to the surface of the caecum using the tumour patch
technique described by Hirst et al. (1993). Seven days after
the initial i.d. transplant 3-5 x I05cells were injected into
the gastrocnemius muscle (i.m.). Relative perfusion
measurements were carried out in half of the animals 21 ± 1
days after the implantation of the i.d. tumour (day 21) and
four days later (day 25) in the remaining mice to allow
comparisons to be made between tumours of different
sizes.
Animals (n = 84) bearing all three tumours were treated in
three separate experiments, whilst two separate experiments
were carried out on mice bearing single tumours located
either intradermally (n = 36), intramuscularly (n = 39), or on
the caecum wall (n = 37).
Measurement ofhaematocrit
The packed cell volume (haematocrit) of each mouse was
measured prior to treatment with PTX. A small volume of
blood (<101l) was collected in a glass capillary tube (10 ,lI)
from a cut in the tip of the tail, which had been pre-heated
under a lamp. The capillary tube was sealed at one end
(Cristaseal (Hawksley)) and placed in a microhaematocrit
centrifuge (Hawksley). The tubes were spun at maximum for
5 min and the haematocrit was calculated from the ratio of
the red cell content to the total volume in each tube.
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Treatment with PTX
A 5 mg ml-' solution of PTX (Sigma Chemical Co.) was
prepared in physiological saline. The mice were weighed and
the PTX was administered i.p. so that the mouse received a
total dose of 50 mg kg'. This dose has been shown to be
sufficient to elicit an increase in the relative perfusion of
subcutaneous RIF-I tumours (Honess, 1991). PTX was
administered 15 min prior to the measurement of relative
perfusion.
Measurement ofthe relative distribution ofthe cardiac output
The COD to each tumour and to several normal tissues,
including the gastrocnemius muscle from the contralateral leg
to the site of the i.m. tumour, the liver, the kidney, the
spleen, the gut and the tail, was measured 15 min after
treatment with PTX, using the 86Rb extraction technique
(Sapirstein, 1958). 185 kBq 86RbCl (Amersham International,
UK) was injected in a volume of 100 ftl into the tail vein.
After 1 min the mouse was killed and the tail, tumours and
selected tissues were excised and weighed in individual tubes.
The radioactivity of each tissue was counted in a gamma-
counter (1282 CompuGamma Gamma Counter, LKB Wal-
lac) over a 15 min period, or until 1000 counts were
measured, and the percent injected activity in 1 gram of
tissue was calculated by comparing with the activity of 100Il
aliquots of the isotope. Where more than 20% of the injected
activity remained in the tail, the results were discarded and
not included in any analysis. The COD has been expressed
both as %cpm g' tissue and as a percentage of control
values obtained by comparing values in treated animals on
day 21 and day 25 with their respective untreated groups
(Distribution of the Cardiac Output (% Control)).
Results
Tumour size and haematocrit
A significant increase in the weight of each tumour was
recorded between the two days on which COD was measured.
On both days, the tumour size of single tumour-bearing
animals was similar to the size of the same tumour in those
animals in which all three tumours were present (Table
I).
Reductions in haematocrit (HCT) were closely related to
increases in total tumour burden (Figure 1; r2 = 0.876), rang-
ing from 46.69 ± 0.58% in the small i.m. tumours to
29.17 ± 0.73% in animals bearing three relatively large
tumours. The HCT of five non-tumour bearing mice was
measured as 48.58 ± 0.53%.
The effect ofPTX on the distribution ofthe cardiac output in
animals bearing a single tumour
In animals bearing only one tumour, a significant increase in
the COD from 1.641 ± 0.191 %cpm g-' to 2.284 ± 0.178
%cpm g' was measured in tumours located on the caecum
wall when the tumour size was 439 ± 52 mg (P<0.05). This
tendency persisted for the larger caecum tumours although
the effect was not statistically significant. The COD to
tumours located in either the i.d. or the i.m. site was not
significantly altered by PTX (Figure 2).
The only consistent effect of PTX treatment on the COD
to the other tissues excised was the increased perfusion of the
spleen (Figure 2). This occurred when both relatively small
(P<0.01) and comparatively large (P<0.05) tumours were
present, an increase in tumour size itself resulting in an
increased proportion of the cardiac output reaching the
spleen (P<0.05). The COD to the liver was increased
significantly by PTX in those animals bearing i.d. or i.m.
tumours (P<0.05), but not in those with tumours located on
the caecum. Relative hepatic flow was greater following an
increase in tumour volume, an increase that was not
significantly augmented by PTX treatment. PTX had no
effect on the relative perfusion of any of the other tissues
excised.
The effect ofPTX on the distribution ofthe cardiac output in
animals bearing tumours located in three sites
Treatment of animals bearing all three tumours with PTX
resulted in significant increases in the distribution of the
cardiac output to the i.d. (P<0.01), i.m. (P<0.05) and
caecum tumours (P<0.01) (Figure 3). The effect was main-
tained in the i.d. and caecum tumours following an increase
in tumour weight from 312 ± 54 mg and 503 ± 36 mg to
541 ± 30 mg and 849 ± 53 mg, respectively. An increase in
tumour burden significantly reduced the COD to these two
tumours and tended to lower the COD to the i.m. tumour
(Figure 3).
In general, the COD to each tumour was lower if all three
tumours were present (Table II). In the smaller tumours this
effect was only of statistical significance in the i.d. site
(P<0.05), whilst it was statistically significant in all three
locations following an increase in tumour mass (P<0.01).
As in animals with a single tumour, the COD to the spleen
was significantly increased following PTX treatment
(P<0.001). Of the other organs studied only the liver
received a significantly greater proportion of the cardiac
output following PTX treatment, but only when the tumour
burden was relatively low (P<0.01).
Discussion
The manipulation of tumour blood flow is widely recognised
as an important factor in the treatment of cancer and the
relative effectiveness of several agents in animal tumour
model systems is now well-established. Recently it has been
shown that the way in which the blood flow to tumours is
modified by different agents, such as hydralazine, angiotensin
II and nicotinamide, and under anaemic conditions varies
depending on the location of the tumour (Hirst et al., 1991;
Hirst et al., 1993; Sensky et al., in press). The interest regard-
ing the haemorheological agent, pentoxifylline, as a potential
radiosensitiser prompted us to see if it modified tumour
perfusion in a consistent or variable manner, dependent on
tumour site.
Table I Tumour sizes and corresponding haematocrits (HCT) in mice bearing tumours in
one, or each, of three different sites on the two days on which COD was measured (Day 21
and Day 25)
No of tumours Tumour Day 21 Day 25
in animals site HCT Size (mg) HCT Size (mg)
i.d. 46.22±0.32 217 12 41.07±0.61 419+30
One i.m. 46.69 0.58 63 10 46.85 0.56 134 21
caecum 38.48 ± 0.98 439 ± 52 36.95 ± 1.82 800 ± 60
i.d. 312±54 541±30
Three i.m. 40.26 0.78 92 7 29.17 0.73 294± 21
caecum 503 ± 36 849± 531112 P.L. SENSKY et al.
The data presented indicate that the effectiveness of PTX
in increasing relative tumour perfusion is, indeed, dependent
on the site of tumour growth. This is immediately evident
from the non-responsiveness of tumours located in the intra-
dermal or intramuscular site compared with the enhanced
perfusion of the caecum tumours in animals bearing a single
tumour. It may be argued that the discrepancies in the size of
tumours in each location may account for this difference. The
tumour sizes studied were those which could typically be
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Figure 1 The effect of total tumour burden on haematocrit (O
i.m. tumours only; 0 i.d. tumours only; 0 caecum tumours only;
* all three tumours).
accommodated in their respective sites without causing gross
disruption of any surrounding normal tissue. Although it
may be possible that PTX does not modify the COD to very
small caecum tumours, i.e. <100 mg, the comparison
between the effectiveness of PTX on the COD to i.d. tumours
on day 25 and that to the caecum tumours on day 21,
indicates that even if the size of tumour is similar, i.e.
419 ± 30 mg and 439 ± 52 mg, respectively, a significantly
different effect occurs in the two sites. The HCT of the
animals in these two groups were also not significantly
different, i.e. 41.07 ± 0.61 and 38.48 ± 0.98, respectively.
Consequently, the improved perfusion of the caecum
tumours following PTX treatment does not appear to be
controlled by changes in HCT either. This is supported by
observations that PTX is able to increase the filterability of
red cells in a 5% suspension (Dormandy et al., 1981) as well
as reverse the rigidifying action of endotoxin on whole blood
(Mollitt & Poulos, 1991), implying that PTX is equally
effective over a wide range of haematocrits. Thus, whilst
increasing the tumour burden significantly affects the HCT of
the animal, it is unlikely that either parameter is responsible
for the site specific response of the CaNT tumour to
PTX.
This site dependent response suggests that there may be
significant differences in the microenvironments of the three
tumours, such as temperature, nutrient availability and vas-
cularisation, although the data does not permit a more
detailed conclusion.
PTX exerts its haemorheological effects at several different
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Figure 2 Changes in the distribution of the cardiac output to single tumours located either on the wall of the caecum,
intradermally (i.d.) or intramuscularly (i.m.) and selected other tissues following treatment with PTX. Experiments were performed
either 21 (d21) or 25 days (d25) after implantation of the i.d. tumour. Statistical comparisons are between untreated and PTX
treated animals on each day and between control animals on d21 and d25. The values represent pooled data. (0 Untreated; O
PTX treated; P<0.05, '*P<0.01; ...P<0.001).
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Table 11 The relative distribution of the cardiac output (COD) to intradermal (i.d.),
intramuscular (i.m.) and caecum tumours in untreated animals and in animals treated with
pentoxifylline (+ PTX). Tumours are present in either each individual site or in all three
COD (% c.p.m.g-')
I or 3 Da) 21 DaY 25
Tumour site Tumours Control + PTX Control + PTX
i.d. 3 0.933 ± 0.077 1.228 ± 0.102 0.569 ± 0.066 0.897 ± 0.063
1 1.289 0.185 1.163 0.123 1.061 0.166 0.787 0.060
i.m. 3 1.404±0.117 1.641 0.132 1.030±0.151 1.253±0.096
1 1.888 0.381 1.884 0.132 1.725 0.137 2.022 0.114
caecum 3 1.455 0.151 1.919 0.146 0.947 0.100 1.445 0.096
1 1.641 0.191 2.284 0.178 1.475 0.176 1.690 0.145
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Figure 3 Changes in the distribution of the cardiac output to
selected tissues and to tumours located on the wall of the caecum,
intradermally (i.d.) and intramuscularly (i.m.) in animals bearing
all three tumours, following treatment with PTX. Experiments
were performed either 21 (d21) or 25 days (d25) after implanta-
tion of the i.d. tumour. Statistical comparisons are between un-
treated and PTX treated animals on each day and between
control animals on d21 and d25. The values represent pooled
data. (0 Untreated; * PTX treated; *P<0.05, **P<0.01;
**P<0.00 1).
levels, resulting ultimately in a reduction in viscosity as a
consequence of an increased membrane flexibility or the
dissolution of clusters of red blood cells, i.e. rouleaux. Both
erythrocyte rigidity and rouleaux formation are known to be
prevalent in the tumour microcirculation (Jain, 1988). Thus it
is possible that local factors produce more marked changes in
the erythrocytes present in the microvasculature of the
caecum tumours than those in either of the other two
tumours. The data presented do not allow us to define these
local effects more clearly, although it can be postulated that
factors which enhance either red cell rigidity, e.g., reduced
red cell 2,3-diphosphoglycerate (2,3-DPG) content and raised
intracellular glucose, or the formation of rouleaux, e.g., low
shear rates and the presence of platelets or macromolecules,
such as fibrinogen, may be more evident in the deep-seated
caecum tumour. There is evidence to suggest that the factors
influencing red cell membrane flexibility can be overcome by
treatment with PTX (Aviado & Porter, 1984; Dion et al.,
1989). The anti-platelet action of PTX, mediated by the
release of prostacyclin from the endothelial cells is also well
documented (Gastpar et al., 1978; Ambrus et al., 1979;
Weithmann, 1981). In addition, the release of prostacyclin
stimulates fibrinolysis (Jarrett et al., 1977). PTX has also
been shown to reduce the adhesion of erythrocytes to
endothelial cells, thereby increasing the shear rate
(Sowemimo-Coker & Turner, 1985). Thus, any one, or any
combination of these, could be more prevalent in the caecum
tumour than in the i.d. or i.m. sites, although a more detailed
study needs to be undertaken.
For PTX to exert an effect we are assuming that the
viscosity must be raised, since there is no direct evidence that
PTX affects the in vivo blood viscosity under normal condi-
tions. Attempts to measure the blood viscosity proved to be
unreliable, due to the time lapse between sampling and
measurement and the change in the environmental conditions
of the blood, a phenomenon that has been experienced before
(Hirst & Wood, personal communication). However, the
COD to the spleen may provide a means of assessing how
blood viscosity was modified.
The spleen acts as a sieve to trap aged red blood cells for
cellular degradation, making it an organ resistant to the
passage of erythrocytes. In this respect, the spleen can be
regarded as a highly sensitive 'test' organ for detecting any
changes in blood viscosity, i.e., if PTX treatment increases
the COD to the spleen, then the viscosity of the blood prior
to PTX administration must have been greater than normal.
This may even prove to be a highly accurate means of
detecting changes in in vivo blood viscosity. Therefore, the
increased COD to the spleen in all animals following PTX
treatment (Figure 2) suggests that the viscosity was raised
whenever the tumour was present. The fact that the COD to
the tumours located in the i.d. and i.m. sites was not im-
proved by PTX suggests that the viscosity was not increased
sufficiently to elicit a PTX mediated response. Indeed, the
splenic COD was increased to 183 ± 14% control values in
animals bearing caecum tumours, whilst it was only increased
to 153 ± 17% and 147 ± 32% control values in the i.d. and
i.m. sites, respectively (Figure 2). This argument must, how-
ever, remain speculative in the absence of further data.
The increased COD to all three tumours following PTX
treatment in animals bearing tumours located in all three
sites appears to confuse the issue. It may be that local
changes in viscosity of blood passing through the caecum
tumour has an effect on the viscosity of the blood as a whole,
so that if viscosity is raised sufficiently in one site, PTX will
be equally effective in other locations. This hypothesis is
supported by the data for the modification of splenic blood
flow. Alternatively, whilst tumour weight may not influence
the effects of PTX in single tumour bearing animals, an
increase in tumour burden arising from more than one
tumour site may have profound effects on the rheological
properties of the blood of these animals. Thus, when assess-
ing the potential of PTX as a radiosensitising agent it is
important to realise that its effectiveness may be highly
dependent on the location of the tumour to be treated.
---.-j1114 P.L. SENSKY et al.
Reports that the COD to RIF-1 tumours and the oxygena-
tion of FSaII and SCK tumours implanted in subcutaneous
sites are enhanced following PTX treatment (Honess, 1991;
Lee et al., 1992; Song et al., 1992) suggests that the tumour
response to PTX is also tumour type dependent. This site-
dependency could have important implications for the use of
PTX in the treatment of cancer.
We would like to thank Mr P. Russell and his staff for the care of
the animals. This work is funded by the Cancer Research Cam-
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